BIMEKIZUMAB SHOWS SUSTAINED LONG-TERM IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY

被引：0

作者：

Baraliakos, X. ^{[1
]}

Dougados, M. ^{[2
]}

Gaffney, K. ^{[3
]}

Sengupta, R. ^{[4
]}

Magrey, M. ^{[5
]}

De Peyrecave, N. ^{[6
]}

Oortgiesen, M. ^{[7
]}

Vaux, T. ^{[8
]}

Fleurinck, C. ^{[6
]}

Deodhar, A. ^{[9
]}

机构：

[1] Ruhr Univ Bochum, Rheumazentrum Ruhrgebiet Herne, Herne, Germany

[2] Hop Cochin, Dept Rheumatol, Paris, France

[3] Norfolk & Norwich Univ Hosp NHS Trust, Dept Rheumatol, Norwich, Norfolk, England

[4] Royal Natl Hosp Rheumat Dis, Dept Rheumatol, Bath, Avon, England

[5] Case Western Reserve Univ, MetroHlth Med Ctr, Cleveland, OH 44106 USA

[6] UCB Pharma, Brussels, Belgium

[7] UCB Pharma, Raleigh, NC USA

[8] UCB Pharma, Slough, Berks, England

[9] Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, Portland, OR 97201 USA

来源：

关键词：

D O I：

10.1136/annrheumdis-2021-eular.1840

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

POS0919

引用

页码：720 / 721

页数：2

共 4 条